Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 17, 2009 01:00 ET | Source: BiPar Sciences

BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer

PARIS and SOUTH SAN FRANCISCO, Calif., July 17, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its wholly owned subsidiary, BiPar Sciences, today announced the initiation of the...
May 31, 2009 08:30 ET | Source: BiPar Sciences

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients With Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

PARIS and BRISBANE, Calif., May 31, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2...
May 20, 2009 03:00 ET | Source: BiPar Sciences

In Prüfung befindlicher PARP-Inhibitor von BiPar Sciences, BSI-201, im Scheinwerferlicht der ASCO-Vollversammlung

BRISBANE, Kalifornien und PARIS, 20. Mai 2009 (GLOBE NEWSWIRE) -- Die Ergebnisse der Phase II einer klinischen Studie von BiPar Science - einem Tochterunternehmen im Besitz von sanofi-aventis - über...
May 18, 2009 13:56 ET | Source: BiPar Sciences

BSI-201, le nouveau inhibiteur PARP de BiPar Sciences, sera un moment fort de la séance plénière du congrès annuel

Les données de phase II du BSI-201 dans le cancer du sein métastatique triple négatif seront présentées lors d'une conférence de presse officielle de l'ASCO et intégrées au programme de formation «...
May 18, 2009 13:56 ET | Source: BiPar Sciences

BiPar Sciences' Investigational PARP Inhibitor, BSI-201, to be Highlighted During ASCO's Plenary Session

BSI-201 Phase II Data in Metastatic Triple-Negative Breast Cancer Featured At ASCO Press Briefing; Study Results Will be Released On Sunday, May 31, 2009, At 8:30 a.m. EDT (Orlando, FL)...
May 18, 2009 13:21 ET | Source: BiPar Sciences

BiPar Sciences' Investigational PARP Inhibitor, BSI-201, to be Highlighted During ASCO's Plenary Session

BRISBANE, Calif. and PARIS, May 18, 2009 (GLOBE NEWSWIRE) -- Results from a Phase II clinical trial of BiPar Sciences' -- a wholly-owned sanofi-aventis subsidiary -- lead PARP inhibitor, BSI-201, will...
April 15, 2009 03:01 ET | Source: BiPar Sciences

Sanofi-aventis to Acquire BiPar Sciences, a US Biopharmaceutical Company

BRISBANE, Calif. and PARIS, April 15, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) announced today that it has signed a binding agreement for the acquisition of BiPar Sciences,...
February 03, 2009 09:30 ET | Source: BiPar Sciences

BiPar Sciences to Present At the 11th Annual BIO CEO & Investor Conference in New York City

BRISBANE, Calif., Feb. 3, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that President...
January 12, 2009 09:00 ET | Source: BiPar Sciences

BiPar Sciences Raises $20 Million to Advance Clinical Programs

BRISBANE, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today it has raised...
January 07, 2009 09:00 ET | Source: BiPar Sciences

BiPar Sciences to Present At the 27th Annual JP Morgan Healthcare Conference in San Francisco

BRISBANE, Calif., Jan. 7, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that Hoyoung...